{"entity":{"id":"cto1681","kind":"drug","name":"CTO1681","aka":["GP1681"],"tldr":"CTO1681 is a tablet from CytoAgents meant to prevent and treat cytokine release syndrome, an immune over-reaction that can follow CAR-T cell therapy for blood cancers.","summary":"CTO1681 is CytoAgents' oral anti-inflammatory compound. ClinicalTrials.gov lists NCT05905328, a phase 1/2 study sponsored by CytoAgents of CTO1681 for the prevention and treatment of cytokine release syndrome in patients receiving CAR T-cell therapy, as recruiting. A 2026 National Cancer Institute SBIR award to CytoAgents extends the work to people with multiple myeloma receiving CAR T-cell therapy. It is a supportive medicine: it is not meant to treat the cancer itself.","status":"phase-2","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov: NCT05905328","url":"https://clinicaltrials.gov/study/NCT05905328"},{"label":"NIH RePORTER: award 5R44CA295189-02","url":"https://reporter.nih.gov/project-details/11418976"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cytoagents"],"institutions":[],"pathways":[],"terms":["crs"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"CTO1681","modality":"Oral small molecule","mechanism":"Described by CytoAgents as a steroid-sparing inhibitor of prostaglandin and prostacyclin-mediated inflammation, given by mouth to damp the cytokine surge of cytokine release syndrome.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cto1681/","neighbours":{"company":[{"id":"cytoagents","kind":"company","name":"CytoAgents","route":"/companies/cytoagents/"}],"term":[{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"}]}}